Changes in Glutamatergic Neurotransmission of Severe TBI Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

EARLY_PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-23

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Studies in patients with disorders of consciousness (DOC) after severe brain injury implicate dysfunction of the anterior forebrain mesocircuit dysfunction a key underlying mechanism. The anterior forebrain metabolism in DOC is markedly downregulated across brain regions underpinning highly elaborated cognitive behaviors demonstrating a collapse of the level of synaptic background activity required for consistent goal-directed behavior and arousal regulation. Since dopamine levels are one of the primary controllers of the level of synaptic background activity within these forebrain structures and in regulating excitatory glutamatergic homeostasis, the investigators propose to investigate the specific contribution of presynaptic dopamine function in glutamatergic neurotransmission in posttraumatic DOC. The aim of the present study is to measure metabotropic glutamate receptors 5 occupancy in the main gutamatergic structures of the brain using (3-\[18F\]fluoro-5-(2-pyridinylethynyl)benzonitrile)-positron emission tomography ( \[18F\]FPEB-PET) at rest and following a short pharmacological challenge with amantadine, an N-methyl-D-aspartate receptor (NMDA-R) antagonist, following L-DOPA, and amantadine + L-DOPA. Using this novel technique in DOC the investigators will characterize the relevance of a presynaptic deficiency to synthesize and/or release dopamine in the final regulation of excitatory interneurons of the anterior forebrain mesocircuit.

It is unknown whether glutamatergic neurotransmission is affected across the population of subjects with DOC and, if this condition is secondary to a presynaptic dopaminergic failure of the anterior forebrain mesocircuit (i.e., down-regulation). Since the investigators previously identified the existence of a presynaptic dopaminergic deficit in these subjects due to a failure in the biosynthesis of dopamine, the investigators will evaluate if by providing the main biological substrate of the biosynthesis process (i.e., L-DOPA) the glutamatergic system regains homeostasis. The investigators therefore propose to investigate patients with posttraumatic DOC using \[18F\]FPEB-PET at rest and following short pharmacological challenges aimed at increasing glutamate and dopamine release.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury

NCT02240589

Traumatic Brain Injury

COMPLETED NA

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

NCT00462228

Traumatic Brain Injury

TERMINATED PHASE4

Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes

NCT00504894

Healthy

TERMINATED PHASE4

Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI

NCT00489892

Traumatic Brain Injury Severe Traumatic Brain Injury

UNKNOWN NA

The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)

NCT02015949

Traumatic Brain Injury

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disorders of consciousness (DOC) produced by severe traumatic brain injuries (TBI) lack systematic evaluation and treatment strategies. Accumulating evidence points to the important and general role of impaired anterior forebrain mesocircuit function following multi-focal brain injuries that produce widespread deafferentation or neuronal cell loss (Schiff, 2010, Fridman et al. 2014). Among important sources of neuromodulation of this mesocircuit, alteration of dopaminergic innervations as a result of impaired biosynthesis of dopamine, neurotransmitter release, or its direct binding to dopamine receptors is implicated as having a critical contribution (Fridman and Schiff, 2014, Giacino et al. 2012). Parallel deficits of long-range excitatory glutamatergic neurotransmission likely play an equally crucial factor in all DOCs (Fridman and Schiff, 2014), as shown in non-human primates where a decrease of cortical glutamate levels occurs following dopamine depletion of substantia nigra (SN), and likely the ventral tegmentum (VT) (Fan et al., 2014). In a Phase 0 clinical trial exploring the pharmacodynamics underlying DOC (NINDS R21-NS093268) the investigators have shown that chronic TBI patients have an underlying presynaptic dopamine deficit in SN and VT that is not reversed by blocking only dopamine reuptake but is reversed by increasing dopamine synthesis using the dopamine precursor L-DOPA (Fridman et al., 2018)\*. No prior studies, however, have provided direct measurements of glutamatergic deficits in DOC. Moreover, no systematic evaluation of glutamatergic neurotransmission has been carried in post-TBI DOC patients following dopaminergic modulation. This gap in knowledge is critically important as only one therapeutic intervention has shown modest effectiveness in subacute and chronic stage of TBI (Giacino et al., 2012) targeting glutamatergic neurotransmission without addressing impaired dopaminergic biosynthesis (Fridman et al., 2018)\*.

Here the investigators develop a novel and systematic assessment focusing on the role of the integrity of dopaminergic-glutamatergic systems in DOC. The investigators approach allows for evaluation of the integrity of glutamatergic innervations to key neuronal populations within the anterior forebrain mesocircuit. Using a similar approach (i.e., molecular neuroimaging and pharmacological challenges), the investigators have identified that patients with DOC exhibit: 1) a widespread presynaptic deficit affecting the resting dopamine synaptic activity; 2) a widespread presynaptic deficit affecting the induced dopamine release after pharmacological stimulation with amphetamine; and, 3) a partial postsynaptic deficit. The investigators long-term goal is to understand how neuromodulation of the anterior forebrain mesocircuit in DOC can be optimally manipulated for diagnosis and therapy. The investigators working hypothesis is that patients with DOC following TBI have alterations of glutamatergic function that can be partially reversed by dopamine replacement. The rationale that underlies the proposed research is that identification of a glutamatergic down-regulation in DOC as well as identification of the key regulator of this down-regulation (i.e., secondary to a deficit in the synthesis of dopamine) will allow the development of complementary diagnostic methods to predict patients' responses to specific therapies and, further improve the efficacy of neuropharmacological treatments to induce recovery of consciousness following severe TBI by rational polypharmacy. The investigators will develop quantitative measurements to test this hypothesis under the following Specific Aims:

Specific Aim 1a. To identify and characterize impaired glutamatergic neurotransmission deficits in posttraumatic DOC.

The investigators will assess in-vivo the availability of free metabotropic glutamate receptor 5 (mGluR5) at rest in patients with DOC and normal volunteers (NV) following N-methyl-D-aspartate receptor (NMDA-R) blockade with amantadine (AMT) utilizing \[18F\]FPEB-PET. The investigators working hypothesis is that patients with DOC will demonstrate:

1\) a glutamatergic deficit in anterior forebrain mesocircuit that is identified by a lower mGluR5 availability at rest; and 2) a failure to decrease mGluR5 occupancy following stimulation with AMT.

Specific Aim 1b. To determine the reversibility of glutamatergic neurotransmission deficits in response to dopamine replacement in posttraumatic DOC.

In DOC patients with a demonstrated glutamatergic deficit the investigators will assess the availability of free mGluR5 at rest and following NMDA-R blockade with AMT by means of \[18F\]FPEB-PET after premedication with L-DOPA. The investigators hypothesize that impaired glutamatergic neurotransmission in DOC can be partially restored by providing the dopamine precursor L-DOPA and thus supporting dopamine biosynthesis and subsequent release of a circuit- level inhibition at the level of the thalamus (mesocircuit hypothesis). Impaired biosynthesis is proposed to arise secondary to a posttraumatic enzyme tyrosine hydroxylase deficiency affecting the biosynthesis of dopamine.

The investigators expected outcomes are anticipated to identify biomarkers to better define future therapeutic interventions in TBI patients with DOC. These results are expected to have an important positive impact because the identified biomarkers are highly likely to provide new therapeutic targets to induce recovery and therefore decrease disability and social cost in this large population of severe brain injured patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disorder of Consciousness Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Participants will be unaware of the medication used during the pharmacological challenge for the PET approach.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NMDA blocker

Comprehensive functional analyses of dynamic \[18F\]FPEB-PET signal at rest will be carried out in normal volunteers and patients with DOC due to severe brain injury over a 24-month time period. In each study, we will first evaluate mGluR5 occupancy within the frontal cortex, anterior cingulate cortex, insula, striatum and thalamus. Then, a single dose of amantadine (AMT), a compound that blocks NMDA-R and increases glutamate levels at the synaptic cleft, will be given to each subject or patient and at the time corresponding to the peak of the dose, a second \[18F\]FPEB-PET will be acquired.

Group Type ACTIVE_COMPARATOR

NMDA blocker

Intervention Type DRUG

NMDA blocker

NMDA blocker + L-DOPA

All the patients with DOC that participate in ARM 1 will follow the same methodology of ARM 1: measurement of mGluR5 occupancy at rest and following NMDA-R blockade with AMT by means of \[18F\]FPEB-PET after premedication with L-DOPA introduced 1 hour prior each \[18F\]FPEB-PET acquisitions.

Group Type EXPERIMENTAL

Amantadine + L-DOPA

Intervention Type DRUG

Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amantadine + L-DOPA

Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg

Intervention Type DRUG

NMDA blocker

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 75 years of age, inclusive.
* Patients with disorder of consciousness (vegetative state, minimally conscious state, emerged from minimally conscious state) following severe brain injuries.
* Male or non-pregnant female.
* Medically stable.
* Informed consent from a Legally Authorized Representative.

* Age between 18 and 75 years old, inclusive.
* Absence of cardiological, neurological and/or psychiatric diseases.
* Absence of familiar antecedents of sudden death of unknown reason.
* Male or non-pregnant female.
* Informed consent signed.

Exclusion Criteria

* Medical instability.
* Clinical history of moderate to severe hypertension or heart arrhythmia.
* Use of stimulants or dopamine blocker during the 24 hours previous to the study.
* Absence of a legally authorized representative (LAR) to sign the consent form.

Normal Volunteers

\- Caffeine or alcohol intake in the last 24 hours previous to the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes